bioprosthetic (tissue) heart valve

From Aaushi
Jump to navigation Jump to search

Classification

Advantages

* There is a risk of systemic embolization in patients with atrial fibrillation, especially with a prosthetic mitral valve.

Disadvantages

  • tissue valves degenerate & calcify
  • 50% of patients will need valve replacement in 18-20 years[3] (previously 10 years)
  • calcific degeneration of bioprosthetic valves is accelerated in children, adolescents & young adults

Diagnostic procedures

Management

Notes

More general terms

References

  1. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 55-56
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 16, 17. American College of Physicians, Philadelphia 1998, 2006, 2012, 2015
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  3. 3.0 3.1 Ardehali A, Chief of Cardiothoracic Surgery, VAGLA Advances in Cardiothoracic Surgery Medical Staff Meeting, Wadsworth Theater Veterans Administration, Greater Los Angeles Health Care Jan 23, 2009
  4. Merie C et al Association of Warfarin Therapy Duration After Bioprosthetic Aortic Valve Replacement With Risk of Mortality, Thromboembolic Complications, and Bleeding JAMA. 2012;308(20):2118-2125. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23188028 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1456069
    Mehta SR and Weitz JI Warfarin After Bioprosthetic Aortic Valve Implantation JAMA. 2012;308(20):2147-2148 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23188033 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1456031
  5. 5.0 5.1 Foroutan F, Guyatt GH, O'Brien K et al Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies. BMJ. 2016 Sep 28;354:i5065. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27683072 Free PMC Article
  6. 6.0 6.1 Guimaraes HP et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020 Nov 14; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33196155 https://www.nejm.org/doi/10.1056/NEJMoa2029603